全文获取类型
收费全文 | 17488篇 |
免费 | 1330篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 182篇 |
儿科学 | 456篇 |
妇产科学 | 381篇 |
基础医学 | 2068篇 |
口腔科学 | 242篇 |
临床医学 | 2150篇 |
内科学 | 3675篇 |
皮肤病学 | 219篇 |
神经病学 | 1466篇 |
特种医学 | 641篇 |
外国民族医学 | 1篇 |
外科学 | 3000篇 |
综合类 | 164篇 |
一般理论 | 14篇 |
预防医学 | 1540篇 |
眼科学 | 298篇 |
药学 | 1019篇 |
中国医学 | 16篇 |
肿瘤学 | 1331篇 |
出版年
2023年 | 174篇 |
2022年 | 351篇 |
2021年 | 861篇 |
2020年 | 454篇 |
2019年 | 639篇 |
2018年 | 734篇 |
2017年 | 529篇 |
2016年 | 519篇 |
2015年 | 688篇 |
2014年 | 850篇 |
2013年 | 1000篇 |
2012年 | 1484篇 |
2011年 | 1564篇 |
2010年 | 782篇 |
2009年 | 578篇 |
2008年 | 1064篇 |
2007年 | 1001篇 |
2006年 | 1000篇 |
2005年 | 838篇 |
2004年 | 709篇 |
2003年 | 675篇 |
2002年 | 581篇 |
2001年 | 140篇 |
2000年 | 106篇 |
1999年 | 115篇 |
1998年 | 92篇 |
1997年 | 80篇 |
1996年 | 72篇 |
1995年 | 63篇 |
1994年 | 42篇 |
1993年 | 64篇 |
1992年 | 82篇 |
1991年 | 75篇 |
1990年 | 68篇 |
1989年 | 63篇 |
1988年 | 49篇 |
1987年 | 42篇 |
1986年 | 37篇 |
1985年 | 48篇 |
1984年 | 55篇 |
1983年 | 30篇 |
1982年 | 29篇 |
1981年 | 24篇 |
1980年 | 24篇 |
1979年 | 25篇 |
1978年 | 24篇 |
1977年 | 23篇 |
1975年 | 23篇 |
1974年 | 24篇 |
1973年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Brittney H. Cotta Margaret F. Meagher Aaron Bradshaw Stephen T. Ryan Gerant Rivera-Sanfeliz 《Expert review of anticancer therapy》2019,19(4):301-308
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
3.
4.
5.
Aaron Pitzele Mohammad Rahimi Eric Armbrecht 《The journal of maternal-fetal & neonatal medicine》2015,28(15):1770-1773
Objective: To determine whether packed red blood cell (PRBC) transfusion affects post-prandial superior mesenteric artery blood flow velocities (SMA BFVs) in very-low birth weight (VLBW) neonates and if so, at what time point after transfusion restoration of previous SMA BFV patterns occurs.Design/Methods: VLBW pre-term neonates, older than 14 days and tolerating bolus enteral feedings administered every 3?h were enrolled in this prospective observational study. Pulsed Doppler ultrasound was used to measure pre- and post-prandial (at 45?min) time-averaged mean, peak and end diastolic velocities (TAMV, PSV, EDV) immediately before and after 15?ml/kg of PRBC transfusion was given over 3?h; patent ductus arteriosus (PDA) status was also evaluated. Subsequent pre- and post-prandial SMA BFVs were recorded 24 and 48?h after the transfusion.Results: Pre- and post-prandial measurements were obtained for 21 out of 25 enrolled infants. Post-prandial SMA BFVs were attenuated during the feedings immediately after transfusion; at 24 and 48?h after transfusion, changes in post-prandial SMA BFVs were similar to those measured prior to transfusion; the presence of the PDA did not affect results.Conclusions: PRBC transfusion blunted SMA BFV responses to feedings immediately after the transfusion with normalization observed 24?h post-transfusion. 相似文献
6.
7.
8.
9.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
10.